Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/176302
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDas, Partha Pratim-
dc.contributor.authorGuzzinati, Giulio-
dc.contributor.authorColl, Cristina-
dc.contributor.authorGómez Pérez, Alejandro-
dc.contributor.authorNicolopoulos, Stavros-
dc.contributor.authorEstradé Albiol, Sònia-
dc.contributor.authorPeiró Martínez, Francisca-
dc.contributor.authorVerbeeck, Johan-
dc.contributor.authorZompra, Aikaterini A.-
dc.contributor.authorGalanis, Athanassios S.-
dc.date.accessioned2021-04-15T09:10:18Z-
dc.date.available2021-04-15T09:10:18Z-
dc.date.issued2020-06-27-
dc.identifier.issn2073-4360-
dc.identifier.urihttp://hdl.handle.net/2445/176302-
dc.description.abstractOrganic and biological compounds (especially those related to the pharmaceutical industry) have always been of great interest for researchers due to their importance for the development of new drugs to diagnose, cure, treat or prevent disease. As many new API (active pharmaceutical ingredients) and their polymorphs are in nanocrystalline or in amorphous form blended with amorphous polymeric matrix (known as amorphous solid dispersion-ASD), their structural identification and characterization at nm scale with conventional X-Ray/Raman/IR techniques becomes difficult. During any API synthesis/production or in the formulated drug product, impurities must be identified and characterized. Electron energy loss spectroscopy (EELS) at high energy resolution by transmission electron microscope (TEM) is expected to be a promising technique to screen and identify the different (organic) compounds used in a typical pharmaceutical or biological system and to detect any impurities present, if any, during the synthesis or formulation process. In this work, we propose the use of monochromated TEM-EELS, to analyze selected peptides and organic compounds and their polymorphs. In order to validate EELS for fingerprinting (in low loss/optical region) and by further correlation with advanced DFT, simulations were utilized.-
dc.format.extent11 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/polym12071434-
dc.relation.ispartofPolymers, 2020, vol. 12, num. 7, p. 1434-
dc.relation.urihttps://doi.org/10.3390/polym12071434-
dc.rightscc-by (c) Das, Partha Pratim et al., 2020-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Enginyeria Electrònica i Biomèdica)-
dc.subject.classificationIndústria farmacèutica-
dc.subject.classificationDaltonisme-
dc.subject.otherPharmaceutical industry-
dc.subject.otherColor blindness-
dc.titleReliable Characterization of Organic & Pharmaceutical Compounds with High Resolution Monochromated EEL Spectroscopy-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec708791-
dc.date.updated2021-04-15T09:10:18Z-
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/731019/EU//EUSMI-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid32605004-
Appears in Collections:Articles publicats en revistes (Enginyeria Electrònica i Biomèdica)

Files in This Item:
File Description SizeFormat 
708791.pdf2.67 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons